Silent Synapses Wake Up: How Dormant Brain Connections Could Reshape Treatment of Disease

Deep inside the brain, a hidden population of connections sits waiting in the dark. These are silent synapses, junctions between neurons that receive signals but refuse to pass them on. For decades they were dismissed as immature leftovers destined for destruction. Today, a comprehensive review published in Frontiers in Synaptic Neuroscience argues that they are anything but disposable: silent synapses form a vast reservoir of untapped plasticity, and the way the brain wakes them up may hold the key to understanding Alzheimer’s disease, depression, addiction, chronic pain, and disorders of brain development.

The story began in 1995, when researchers working in the hippocampal CA1 region of rats discovered synapses that produced no detectable electrical response under baseline stimulation yet could be converted into fully functional excitatory connections by specific patterns of activity. This finding overturned the classical view that synaptic activity alone marks maturity, and that inactive synapses are simply pruned away. Instead, the brain appears to maintain a stockpile of dormant connections that can be recruited on demand, expanding the computational repertoire of neural circuits without growing new structures. The activation state of these synapses directly shapes how circuits remodel during learning, development, and repair.

What makes a synapse silent? At most excitatory synapses, two classes of receptors work in concert. AMPA receptors mediate fast excitatory transmission, while NMDA receptors, blocked by magnesium ions at resting membrane potentials, act as coincidence detectors that require strong depolarization to open. A post-synaptically silent synapse expresses NMDA receptors but lacks a stable, anchored cluster of functional AMPA receptors, so glutamate released by the presynaptic terminal produces no fast response. A presynaptically silent synapse has the opposite problem: AMPA receptors are present, but the terminal cannot release enough neurotransmitter. Structurally, the post-synaptic density, the protein scaffold that anchors receptors, is typically incomplete in silent synapses, providing the physical substrate for their dormancy.

Waking a silent synapse is not a simple on-off switch but a coordinated cascade operating on multiple timescales. On the presynaptic side, action potentials open voltage-gated calcium channels, and calcium surging into the nerve terminal drives a choreography of vesicle dynamics. Proteins such as SV2, RIM, Munc13, and CAPS tether vesicles near calcium channels, assemble the SNARE fusion machinery, and regulate the balance between spontaneous and evoked release. After neurotransmitter release, calcium- and calmodulin-dependent kinases accelerate vesicle recycling, while internal calcium stores and mitochondria sustain the energy and ionic balance needed for high-frequency firing. Over slower timescales of days to weeks, neurons can even remodel their neurotransmitter identity, shifting the balance of vesicular glutamate and GABA transporters under the control of transcription factors, providing a durable structural basis for long-term changes in silent synapse function.

On the post-synaptic side, activation hinges on delivering functional AMPA receptors to the membrane and capturing them at the synapse. Super-resolution imaging and single-molecule tracking reveal that AMPA receptors diffuse continuously in the neuronal membrane, moving between reservoirs and the post-synaptic density. When NMDA receptors open and calcium floods in, the kinase CaMKII self-phosphorylates into a persistently active state and, together with PKC, drives receptors toward the membrane along Rab4 and Rab11 trafficking routes. The scaffold protein PSD-95 then captures arriving receptors through their auxiliary subunit Stargazin, a dynamic equilibrium rather than a static anchor: during high-frequency stimulation, roughly twenty to thirty percent of desensitized receptors detach and are replaced by fresh ones within tens of milliseconds, preserving transmission fidelity. Phosphorylation of the receptor subunit GluA1 and of Stargazin itself tunes this capture efficiency, which, rather than the absolute number of receptors, appears to be the pivotal node deciding whether a silent synapse turns functional.

These local events are orchestrated by an upstream signaling network. Brain-derived neurotrophic factor acting through its TrkB receptor, the calcium-CaMKII axis, the cAMP-PKA pathway, and the MAPK-ERK cascade all converge on the transcription factor CREB, whose phosphorylation at a specific serine residue switches on genes for BDNF, PSD-95, and AMPA receptor auxiliary proteins. This creates a slow positive feedback loop that converts an acute desilencing event into long-lasting enhancement of synaptic strength. Retrograde messengers such as nitric oxide and BDNF itself, synthesized at the post-synaptic side and secreted back onto presynaptic TrkB receptors, help synchronize events across the synaptic cleft. Astrocytes add another layer of bidirectional control: they release D-serine, an essential co-agonist for NMDA receptors, and secrete factors such as hevin and glypicans that first build silent synapses and then mature them, while the inflammatory protein lipocalin-2 can push synapses back into a pathological silent state after brain injury.

The clinical significance of this machinery lies in its two opposite failure modes. In Alzheimer’s disease, depression, and stroke, desilencing is impaired. Amyloid-beta oligomers interfere with vesicle recycling and glutamate receptor function, hyperphosphorylated tau disrupts receptor complexes, and astrocytes lose the maturation factors needed to stabilize synapses, leaving functional connections stranded in a silent state. In depression, synaptic loss and reduced BDNF signaling in the prefrontal cortex and hippocampus likely trap synapses in inactivity, and antidepressant interventions that boost plasticity may work partly by re-enabling desilencing. After ischemic injury, AMPA receptors are internalized and functional synapses revert to silence, yet these dormant connections retain high plasticity and can potentially be reactivated to reconstruct damaged circuits. By contrast, in drug addiction and chronic pain, desilencing runs abnormally hot. Cocaine and morphine rapidly generate new NMDA-only silent synapses in the nucleus accumbens and then unsilence them, forging pathological reward circuits within days. In chronic pain, persistent nociceptive input converts silent synapses along pain pathways into functional ones, lowering transmission thresholds and sustaining central sensitization even after the original stimulus is gone.

Emerging technologies are transforming how researchers probe this hidden layer of brain function. Stimulated emission depletion microscopy resolves the nanoscale arrangement of AMPA receptors, NMDA receptors, and PSD-95 in living tissue, and has revealed that roughly forty percent of hippocampal dendritic spines renew within four days, a turnover invisible to conventional microscopy. Light-sheet fluorescence microscopy maps synaptic loss and glial remodeling across whole brain volumes. Single-cell RNA sequencing and spatial proteomics identify which cell types carry the molecular signatures of desilencing, while optogenetics provides millisecond-precision causal tests, using light-activated channels such as ChR2 to drive presynaptic release and post-synaptic depolarization, or light-driven pumps such as halorhodopsin to silence circuits. In addiction models, optogenetic induction of long-term depression can even re-silence abnormally matured synapses, offering a glimpse of how pathological memories might be undone. Brain-inspired computing and artificial intelligence, including synaptic knowledge graphs and memristor-based models of ion dynamics, add predictive frameworks, though their outputs still require experimental validation.

The translational landscape is already taking shape. Registered clinical trials worldwide now target glutamatergic signaling across epilepsy, treatment-resistant depression, chronic pain, cognitive disorders, schizophrenia, and anti-NMDA receptor encephalitis, with NMDA receptor modulators such as ketamine and memantine and the AMPA receptor antagonist perampanel, already approved for epilepsy, occupying central positions. Funding agencies in China, Europe, and the United States are channeling resources into glutamate receptor pathways, circuit regulation, and neurodegenerative disease mechanisms. Yet the field faces a decisive bottleneck: no molecular probe or genetically encoded reporter can directly identify and track silent synapses in living human tissue. Every current technology infers synaptic state indirectly, from protein distribution, gene expression, or circuit activity. Closing that gap, through PET tracers or cerebrospinal fluid biomarkers capable of reporting silent synapse status, would enable disease staging, target validation, and efficacy monitoring grounded in the synaptic state itself. The deeper lesson of silent synapse research is that disease may not merely strengthen or weaken existing connections; it can hijack the desilencing process itself, seeding network imbalance before symptoms ever appear. Learning to steer that process, in either direction, could redefine how neuroscience treats the disorders of the brain.

Subject of Research: Mechanisms of silent synapse activation and their roles in neurological and psychiatric disease

Article Title: Activation of silent synapses driven by emerging technologies: mechanisms, disease associations, and prospects for clinical translation

Article References: Activation of silent synapses driven by emerging technologies: mechanisms, disease associations, and prospects for clinical translation. (n.d.). https://doi.org/10.3389/fnsyn.2026.1923815

Image Credits: AI Generated

DOI: 10.3389/fnsyn.2026.1923815

Keywords: silent synapses, synaptic plasticity, AMPAR trafficking, NMDA receptors, Alzheimer's disease, depression, drug addiction, chronic pain, optogenetics, super-resolution imaging, astrocytes, clinical translation